Harrow Health Inc. shares fell 3.5% during trading on Thursday, reaching a new 52-week low of $26.96. The ophthalmic pharmaceutical company’s stock remains well below its 50-day and 200-day moving averages, extending its downward trend.
In its recent quarterly report, Harrow posted a loss of $0.46 per share. Analysts had expected a loss of $0.18 per share. Revenue was $70.66 million, slightly above expectations. The earnings miss appears to be weighing on investor confidence, though analyst sentiment remains generally positive.